Physician profile
Edward B Laub
NPI 1215974902
$38,746.00
in general payments reported to CMS, 2019-2025
64 companies · $6,257 in 2025
The $6,257 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,916 · 2020: $4,807 · 2021: $4,092 · 2022: $8,312 · 2023: $3,766 · 2024: $5,596 · 2025: $6,257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Gift: $1,200 · Consulting Fee: $355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,064.34 |
| Gift | $1,200.00 |
| Consulting Fee | $355.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,247.81 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $5,605.16 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $3,374.80 | 2019-2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,355.83 | 2019-2025 | Jardiance, Synjardy |
| Novo Nordisk INC | $1,978.43 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $1,742.02 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $1,701.19 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Sekisui Diagnostics LLC | $1,645.00 | 2022-2025 | |
| Kowa Pharmaceuticals America, INC. | $1,627.86 | 2019-2023 | Seglentis, Livalo |
| Janssen Pharmaceuticals, INC | $1,563.99 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $1,299.68 | 2022-2025 | |
| Amarin Pharma, INC. | $1,051.91 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $819.61 | 2024-2025 | Voquezna |
| Paratek Pharmaceuticals, INC. | $778.19 | 2021-2025 | Nuzyra, Xhance |
| Allergan, INC. | $713.50 | 2019-2020 |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Laub listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.